Evidence map›Paper›PMID 40029548›Full record

ArticleJournal of nephrology2025

Polygenic risk scores for eGFR are associated with age at kidney failure.

Kane E Collins, Edmund Gilbert, Vincent Mauduit, Pukhraj Gaheer, Elhussein A E Elhassan, Katherine A Benson, Shohdan Mohamad Osman, Claire Hill, Amy Jayne McKnight, Alexander Peter Maxwell and 19 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of nephrology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

29 authors.

Kane E CollinsSchool of Pharmacy and Biomolecular Sciences, Royal College of Surgeons in Ireland, Dublin, Ireland.
Edmund GilbertSchool of Pharmacy and Biomolecular Sciences, Royal College of Surgeons in Ireland, Dublin, Ireland.
Vincent MauduitNantes University, Ecole Centrale Nantes, INSERM, Center for Research in Transplantation and Translational Immunology, UMR1064, Nantes, France.
Pukhraj GaheerDivision of Nephrology, Departments of Medicine and Health Research Methodology, Evidence and Impact, St. Joseph's Healthcare Hamilton, McMaster University and Population Health Research Institute, Hamilton, ON, Canada.
Elhussein A E ElhassanDepartment of Nephrology and Transplantation, Beaumont Hospital, Dublin, Ireland.
Katherine A BensonSchool of Pharmacy and Biomolecular Sciences, Royal College of Surgeons in Ireland, Dublin, Ireland.
Shohdan Mohamad OsmanDepartment of Nephrology and Transplantation, Beaumont Hospital, Dublin, Ireland.
Claire HillCentre for Public Health, Queen's University Belfast, Belfast, UK.
Amy Jayne McKnightCentre for Public Health, Queen's University Belfast, Belfast, UK.
Alexander Peter MaxwellCentre for Public Health, Queen's University Belfast, Belfast, UK.
Peter J van der MostDepartment of Epidemiology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
Martin H de BorstDepartment of Internal Medicine, Division of Nephrology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
Weihua GuanDivision of Biostatistics and Health Data Science, School of Public Health, University of Minnesota, Minneapolis, MN, USA.
Pamala A JacobsonExperimental and Clinical Pharmacology, College of Pharmacy, University of Minnesota, Minneapolis, MN, USA.
Ajay K IsraniUniversity of Texas Medical Branch, Galveston, TX, USA.
Brendan J KeatingDepartment of Surgery, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Graham M LordSchool of Immunology and Microbial Sciences, University College London, London, UK.
Salla MarkkinenFinnish Red Cross Blood Service, Research and Development, Biomedicum 1, Helsinki, Finland.
Ilkka HelanteräHelsinki University Hospital, Transplantation and Liver Surgery, Helsinki, Finland.
Kati HyvärinenFinnish Red Cross Blood Service, Research and Development, Biomedicum 1, Helsinki, Finland.
Jukka PartanenFinnish Red Cross Blood Service, Research and Development, Biomedicum 1, Helsinki, Finland.
Stephen F MaddenData Science Centre, Beaux Lane House, Royal College of Surgeons in Ireland, Dublin, Ireland.
Joshua StorrarSalford Royal Hospital, Northern Care Alliance NHS Foundation Trust, Salford, UK.
Smeeta SinhaSalford Royal Hospital, Northern Care Alliance NHS Foundation Trust, Salford, UK.
Philip A KalraSalford Royal Hospital, Northern Care Alliance NHS Foundation Trust, Salford, UK.
Matthew B LanktreeDivision of Nephrology, Departments of Medicine and Health Research Methodology, Evidence and Impact, St. Joseph's Healthcare Hamilton, McMaster University and Population Health Research Institute, Hamilton, ON, Canada.
Sophie LimouNantes University, Ecole Centrale Nantes, INSERM, Center for Research in Transplantation and Translational Immunology, UMR1064, Nantes, France.
Gianpiero L Cavalleri *School of Pharmacy and Biomolecular Sciences, Royal College of Surgeons in Ireland, Dublin, Ireland.
Peter J Conlon *Division of Nephrology, Departments of Medicine and Health Research Methodology, Evidence and Impact, St. Joseph's Healthcare Hamilton, McMaster University and Population Health Research Institute, Hamilton, ON, Canada. peterconlon@beaumont.ie.

Funding

Pharmacogenomics of Immune Suppressants in Kidney TransplantationU19AI070119 · NIAID · UNIVERSITY OF MINNESOTA · PI MATAS, ARTHUR J · 2006 to 2016
$17.1M
Long-term Deterioration of Kidney Allograft FunctionU01AI058013 · NIAID · UNIVERSITY OF MINNESOTA TWIN CITIES · PI MATAS, ARTHUR J · 2005 to 2010
$10.2M
Genetic Variants Associated with Tacrolimus Metabolism in Kidney Transplant RecipientsK01AI130409 · NIAID · HENNEPIN HEALTHCARE RESEARCH INSTITUTE · PI DORR, CASEY R · 2018 to 2022
$724k
CIHR 427810Division of Intramural Research, National Institute of Allergy and Infectious Diseases 5U01-AI058013Division of Intramural Research, National Institute of Allergy and Infectious Diseases 5U19-AI070119Division of Intramural Research, National Institute of Allergy and Infectious Diseases K01AI130409Health Research Board HRCI-HRB-2020-032NIAID NIH HHS K01 AI130409NIAID NIH HHS U01 AI058013NIAID NIH HHS U19 AI070119Science Foundation Ireland 18/CRT/6214The Atlantic Philanthropies and the Economic and Social Research Council ES/L008459/1UK Research and Innovation MC_PC_20026Wellcome TrustWellcome Trust 088849/Z/09/ZWellcome Trust 090355/A/09/ZWellcome Trust 090355/B/09/ZWellcome Trust "WTCCC3"
6 · The paper itself

Abstract

backgroundThe genetic architecture of chronic kidney disease (CKD) is complex, including monogenic and polygenic contributions. CKD progression to kidney failure is influenced by factors including male sex, baseline estimated glomerular filtration rate (eGFR), hypertension, diabetes, proteinuria, and the underlying kidney disease. These traits all have strong genetic components, which can be partially quantified using polygenic risk scores. This paper examines the association between polygenic risk scores for CKD-related traits and age at kidney failure development.

methodsGenome-wide genotype data from 10,586 patients with kidney failure were compiled from 12 cohorts. Polygenic risk scores for hypertension, albuminuria, rapid decline in eGFR, decreased total kidney volume, and decreased eGFR were calculated using weights from published independent population-scale genome-wide association studies. The association between each polygenic risk score and age at kidney failure was investigated using logistic regression models. The association between polygenic risk score and age at kidney failure was also investigated separately for each primary kidney disease.

resultsIndividuals in the highest 10% of polygenic risk score for decreased eGFR developed kidney failure 2 years earlier than those in the bottom 90% (49.9 years and 47.9 years, P = 5e-5). A standard deviation increase in decreased eGFR polygenic risk score was associated with increased odds of developing kidney failure before the age of 60 years (Odds ratio (OR) = 1.05; 95% CI 1.01-1.10; P = 0.01), as was high decreased eGFR polygenic risk score (OR = 1.26; 95% CI 1.08-1.46; P = 0.003).

conclusionsWe conclude that decreased eGFR polygenic risk score explains a portion of the variation in age at development of kidney failure.

Indexed as

Glomerular Filtration RateKidneyMultifactorial InheritanceRenal InsufficiencyRenal Insufficiency, ChronicAdultAgedAge FactorsAge of OnsetDisease ProgressionErbB ReceptorsFemaleGenetic Predisposition to DiseaseGenetic Risk ScoreGenome-Wide Association StudyHumansEGFR protein, humanErbB ReceptorsAge at onsetKidney failureKidney functionPolygenic burdenPolygenic risk score

Identifiers

PMID40029548
PMCPMC12165877

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.